Why This Bullishly Ranked Biotech Stock Just Broke Out To A Record High [Investor's Business Daily]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Investors Business Daily
Related news Shares of Syndax Pharmaceuticals ( SNDX ) soared to a record high Tuesday after the biotech company unveiled promising results for its early-stage blood cancer treatment. Syndax stock jumped more than 50% on the news. Syndax tested its drug, dubbed SNDX-5613, in a total of six patients with hard-to-treat acute leukemia. The cancer treatment works by disrupting the interaction between a protein called menin and a gene known as MLL1. Of those six, three had rearrangements of the MLL1 gene. One of those patients achieved a complete response, while a second partially responded to the cancer treatment, Syndax said in a news release. The third didn't receive sufficient drug exposure to respond. In general, these leukemia patients have a poor prognosis, Chief Executive Briggs Morrison said in a written statement. Their cancer has either relapsed or is refractory, meaning it resists other cancer treatments. "Notably, clinical activity was achieved rapidly after a single, 28-day c
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SNDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.GlobeNewswire
SNDX
Earnings
- 11/3/25 - Beat
SNDX
Sec Filings
- 1/12/26 - Form 8-K
- 12/19/25 - Form 8-K
- 12/1/25 - Form 4
- SNDX's page on the SEC website